Charts

News

27 Apr, 2022
35 years industry experience including as CEO and founder of public company Stephen Squinto steps down as Chair for new role MILAN, Italy and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announced the nomination of Mark A. Sirgo, PharmD, an executive leader with over 35 years of pharmaceutical industry experience, as its new Chair
28 Mar, 2022
What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. ...
22 Mar, 2022
STOUGHTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (“Collegium”) today announced that it has completed the acquisition of BioDelivery Sciences International Inc. (Nasdaq: BDSI) (“BDSI”). “This acquisition is a major step forward in our mission to build a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions,” said Joe Ciaffoni, President and Chief Executive Officer of
Merck's (MRK) Keytruda gets approval for advanced endometrial carcinoma therapy in certain patients who are not suited for curative surgery or radiation.
18 Mar, 2022
Here is how BioDelivery Sciences International (BDSI) and Vertex Pharmaceuticals (VRTX) have performed compared to their sector so far this year.
17 Mar, 2022
Catalyst's (CPRX) fourth-quarter 2021 earnings miss estimates while revenues slightly beat the mark.
15 Mar, 2022
Incyte' s (INCY) sNDA seeking label expansion of ruxolitinib cream gets extended by three months by the FDA for reviewing additional information.
Moderna (MRNA) starts dosing in an mRNA-based HIV vaccine study.
14 Mar, 2022
Novartis (NVS) reports positive data on SMA treatment from a phase III study. It also acquires Coalesce Product Development Limited to strengthen its respiratory and complex generics business.
11 Mar, 2022
Viatris (VTRS) stock drops 25% in the year so far as investors do not seem to be impressed by the impending sale of its biosimilar business.
Intellia's (NTLA) shares decline following the decision of the USPTO, invalidating the patents licensed by Intellia to develop CRISPR-based gene therapies.
10 Mar, 2022
Catalyst's (CPRX) stock price has more than doubled in the past year, driven by its sole marketed drug, Firdapse, approved for the treatment of Lambert-Eaton Myasthenic Syndrome in adults.
Intellia's (NTLA) investigational gene-editing therapy, NTLA-5001, gets an Orphan Drug tag from the FDA for AML.
09 Mar, 2022
Valneva's (VALN) phase III study evaluating its chikungunya vaccine achieves all primary and secondary endpoints. The stock rises 9.2% following the announcement.
08 Mar, 2022
While Gilead's (GILD) phase III study evaluating Trodelvy in late-line HR+/HER- breast cancer did achieve its primary endpoint, the lack of numerical data puts ambiguity on the significance of results.
02 Mar, 2022
BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here is how Hepion Pharmaceuticals, Inc. (HEPA) and BioDelivery Sciences International (BDSI) have performed compared to their sector so far this year.
28 Feb, 2022
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 2.53% and 16.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
25 Feb, 2022
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -35.29% and 90%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
24 Feb, 2022
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Expands BDSI Portfolio and Establishes Growth Platform in Neurology RALEIGH, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced the U.S. commercial launch and availability of ELYXYBTM (celecoxib
22 Feb, 2022
In trading on Tuesday, shares of BioDelivery Sciences International Inc (BDSI) touched a new 52-week high of $5.58/share. That's a 123.20% rise, or $3.08 per share from the 52-week low of $2.50 set back on 12/13/2021..
15 Feb, 2022
Upgrades For Blue Bird Corp (NASDAQ:BLBD), Roth Capital upgraded the previous rating of Neutral to Buy. Blue Bird earned $0.07 in the ...
09:32
FinancialContent
Gainers BioDelivery Sciences International, Inc. (NASDAQ: BDSI) shares climbed 52.8% to close at $5.56 on Monday. Collegium ...
14 Feb, 2022
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Charter Communications Inc (CHTR), where a total of 19,254 contracts have traded so far, representing approximately 1.9 million underlying shares. That amounts to about 133% of CHTR's average daily trading volume over the past month of 1.4 million shares..
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, a big takeover announcement has sent shares of BioDelivery and BDSI stock soaring more than 50% on investor enthusiasm for this deal. The post BDSI Stock Alert: The Deal Sending Little-Known BioDelivery Skyrocketing Today appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...
US stocks traded lower on Monday with the Nasdaq turning negative toward the end of trading amid rising tensions on the border of Russia ...
Stocks are mixed midday, as investors monitor developments between Russia and Ukraine.
US stocks remained mixed midway through trading on Monday amid rising tensions on the border of Russia and Ukraine. The United States ...
BioDelivery Sciences Intl (NASDAQ:BDSI) has outperformed the market over the past 5 years by 10.98% on an annualized basis. Buying ...
Gainers BioDelivery Sciences International, Inc. (NASDAQ: BDSI) shares jumped 51.9% to $5.53. Collegium Pharmaceutical will ...
Markets opened lower on Monday morning, but nothing held these two companies back.
Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of BioDelivery Sciences International, Inc. (NASDAQ: BDSI) to Collegium Pharmaceutical, Inc. for $5.60 per share is fair to BioDelivery shareholders.
US stocks opened on a mixed note this morning amid rising tensions on the border of Russia and Ukraine. The United States said Russia ...
Collegium Pharmaceutical Inc(NASDAQ: COLL) will acquireBioDelivery Sciences International Inc(NASDAQ: BDSI) at $5.60 ...
25 Jan, 2022
09:29
FinancialContent
Gainers Exterran Corporation (NYSE: EXTN) shares surged 59.7% to close at $4.79 on Monday after the company said it would merge ...
24 Jan, 2022
Shares of the small pharmaceutical company, which focuses on pain management, have been rising since it released updated guidance late last week.
Gainers Aridis Pharmaceuticals (NASDAQ:ARDS) shares rose 35.6% to $2.17 during Monday's regular session. The current ...
Gainers Exterran Corporation (NYSE: EXTN) shares jumped 52.4% to $4.5720 after the company said it would merge with Enerflex to ...
10:57
FinancialContent
Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares climbed 100% to close at $3.80 on Friday after gaining around 9% on ...
21 Jan, 2022
Toward the end of trading Friday, the Dow traded down 0.59% to 34,509.34 while the NASDAQ fell 1.38% to 13,958.13. The S&P also ...
Gainers Biophytis (NASDAQ:BPTS) shares rose 12.3% to $5.28 during Friday's regular session. The market value of ...
Midway through trading Friday, the Dow traded down0.33% to 34,602.05while the NASDAQ fell 1.27% to 13,974.28. The S&P ...
Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares jumped 180% to $5.32 after gaining around 9% on Thursday. Bon Natural Life ...
20 Jan, 2022
BioDelivery Sciences International Inc(NASDAQ: BDSI)expects FY21 total revenues of $165-$167 million, compared to previous ...
20 Dec, 2021
The biotech company received a favorable court ruling regarding its lead therapy.
Gainers ACADIA Pharmaceuticals (NASDAQ:ACAD) shares moved upwards by 17.05% to $31.71 during Monday's after-market session. At the ...
15 Dec, 2021
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in United Airlines Holdings Inc (UAL), where a total of 67,432 contracts have traded so far, representing approximately 6.7 million underlying shares. That amounts to about 41.3% of UAL's average daily trading volume over the past month of 16.3 million shares..
14 Dec, 2021
13:08
FinancialContent
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL), we found that the implied analyst target price for the ETF based upon its underlying holdings is $20.23 per unit.
16 Nov, 2021
The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company would choose to take their hard-earned cash and use it to buy stock in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..
12 Nov, 2021
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the WisdomTree US.
10 Nov, 2021
12:54
FinancialContent
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and ...
09 Nov, 2021
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.
05 Nov, 2021
09:01
FinancialContent
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares jumped 95.1% to close at $12.68 on Thursday after dropping over 10% on ...
04 Nov, 2021
Upgrades According to B. Riley Securities, the prior rating for Monroe Capital Corp (NASDAQ:MRCC) was changed from Neutral to Buy. For ...
A look at the weighted underlying holdings of the First Trust Dow Jones Select MicroCap Index Fund (FDM) shows an impressive 10.3% of holdings on a weighted basis have experienced insider buying within the past six months. Start slideshow:10 ETFs With Stocks That Insiders Are Buying » BioDelivery Sciences International Inc (BDSI), which makes up 0.38% of the First Trust Dow Jones Select MicroCap Index Fund (FDM), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data.
02 Nov, 2021
It might have a little trouble after 2026, though.
21 Oct, 2021
07 Oct, 2021
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— SSGA US Small Cap Low Volatility Index ETF (SMLV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $125.23 per unit.
24 Sep, 2021
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in BioDelivery Sciences International Inc (BDSI), where a total of 7,805 contracts have traded so far, representing approximately 780,500 underlying shares. That amounts to about 73.6% of BDSI's average daily trading volume over the past month of 1.1 million shares..
23 Sep, 2021
09:14
FinancialContent
Gainers Marin Software Incorporated (NASDAQ: MRIN) shares jumped 61.9% to close at $9.21 on Wednesday following an announcement ...
22 Sep, 2021
Gainers Marin Software Incorporated (NASDAQ: MRIN) shares climbed 53.1% to $8.71 following an announcement from management that ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...
09 Sep, 2021
27 Aug, 2021
17 Aug, 2021
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in BioDelivery Sciences International Inc (BDSI), where a total of 5,420 contracts have traded so far, representing approximately 542,000 underlying shares. That amounts to about 113.1% of BDSI's average daily trading volume over the past month of 479,350 shares..
05 Aug, 2021
13:35
FinancialContent
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares ESG Aware MSCI USA Small-Cap ETF (ESML), we found that the implied analyst target price for the ETF based upon its underlying holdings is $45.76 per unit.
13 Jul, 2021
A handful of trends might drive BioDelivery Sciences' share price growth.

Related Articles